NYU Langone Health
This is a phase 1 study to examine the safety and tolerability of biology-guided dose intensified hypofractionated radiation therapy (RT) using MR-Linac for patients with high grade glioma (HGG). Investigators will enroll 20 patients with Grade 3 or 4, IDH wild-type (IDHwt), HGG. Intraoperative assessment of residual tumor burden will be performed at 6 surgical margins (anterior, posterior, superior, inferior, medial, lateral) using FastGlioma. Each margin will be graded on a scale of 0 to 3, with 0 being no tumor, 1 atypical cell, 2 sparse tumor infiltration, and 3 dense tumor infiltration.
Inclusion Criteria: * Participants male or female of age 18 or older * Ability to understand and the willingness to sign a written informed consent document * Eastern Cooperative Oncology Group (ECOG) performance status of ≤2. * Have histologically confirmed, newly diagnosed high grade glioma (histologic grade 3 or 4, IDH wildtype) * Must have completed surgery with FastGlioma * Patients can either be consented before or after surgery. Patients can be a maximum of 6 weeks post-surgery period to the start of MRL-RT. * Ability to undergo radiotherapy with an MR-Linac machine including effective…
Elekta Unity is an MR-Linac with continuous, anatomy-specific MR imaging and comprehensive motion management for precision radiation therapy.
Radiation therapy will be delivered twice a week on non-consecutive days for three weeks.
Temozolomide (75 mg/m2) is administered daily throughout the 3 weeks of treatments and stopped on the final day of radiation therapy.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.